Mixed trend on the daily chart: below its 200-day average, above its 50-day · 50-day below the 200-day · SuperTrend up since Sep 1 · above the Ichimoku cloud · RSI 62 · MACD above its signal
| 7.20 | 52-week high | +69.81% |
| 5.09 | R3 (classic) | +20.13% |
| 4.77 | R2 (classic) | +12.42% |
| 4.50 | R1 (classic) | +6.21% |
| 4.44 | Previous day high | +4.72% |
| 4.40 | Previous week high | +3.77% |
| 4.36 | Previous month high | +2.83% |
| 4.24 | Price now | |
| 4.18 | Pivot | −1.49% |
| 3.91 | S1 (classic) | −7.70% |
| 3.85 | Previous day low | −9.20% |
| 3.59 | S2 (classic) | −15.41% |
| 3.38 | Previous week low | −20.28% |
| 3.32 | S3 (classic) | −21.62% |
| 3.10 | Previous month low | −26.89% |
| 3.10 | 52-week low | −26.89% |
| Investor | Value | Of portfolio | Shares | Change | Quarter |
|---|---|---|---|---|---|
| Renaissance Technologies | $379.7K | 0.00% | 98.63K | +28% | Q2 2026 |
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a BOLT trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
| Date | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| Sep 17, 2026 | Yonehiro GrantChief Operating Officer | Sale at price 3.24 - 3.77 per share. | 13.2K | $43.81K |
| Sep 17, 2026 | Quinn William PChief Executive Officer | Sale at price 3.24 - 3.77 per share. | 17.6K | $58.40K |
| Sep 17, 2026 | Nemec SarahOfficer | Sale at price 3.24 - 3.77 per share. | 7.8K | $26.07K |
| Dec 4, 2025 | Quinn William PChief Executive Officer | Purchase at price 4.61 per share. | 125 | $576 |
| Dec 4, 2025 | Nemec SarahOfficer | Purchase at price 4.61 per share. | 125 | $576 |
| Oct 21, 2025 | Yonehiro GrantChief Operating Officer | Stock Award(Grant) at price 0.00 per share. | 30K | — |
| Oct 21, 2025 | Quinn William PChief Executive Officer | Stock Award(Grant) at price 0.00 per share. | 40K | — |
| Oct 21, 2025 | Nemec SarahOfficer | Stock Award(Grant) at price 0.00 per share. | 23K | — |
| Jun 5, 2025 | Quinn William PChief Executive Officer | Purchase at price 0.32 per share. | 125 | $40 |
| Jun 5, 2025 | Nemec SarahOfficer | Purchase at price 0.32 per share. | 125 | $40 |
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 7.9 | -23.4 | -10.6 | 18.8 | 9.4 | -26.7 | 3.6 | -0.3 | -7.5 | 15.2 | −22.5% | ||
| 2025 | -8.4 | -3.1 | -15.8 | -11.3 | -11.3 | -8.4 | -2.1 | -9.2 | 3.7 | 8.3 | -12.0 | 7.9 | −48.9% |
| 2024 | -9.8 | 12.9 | 22.8 | -21.1 | -31.5 | -0.9 | -0.1 | -9.5 | -4.4 | -2.0 | 0.9 | -16.5 | −52.2% |
| 2023 | 13.1 | 9.5 | -13.7 | 13.7 | 8.9 | -25.6 | 5.5 | -18.5 | -5.5 | -5.8 | -13.0 | 31.3 | −13.8% |
| 2022 | -21.6 | -9.1 | -21.5 | -43.1 | 9.0 | 20.0 | 6.4 | -17.1 | -17.8 | -6.1 | 6.5 | -12.2 | −73.5% |
| 2021 | 23.3 | -32.1 | -21.7 | -11.7 | -27.9 | 59.3 | -28.8 | 3.5 | -29.2 | -47.1 | −81.6% |
Buy / hold / sell counts
Bolt Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel immunotherapies for the treatment of cancer. The company's pipeline products include BDC-4182, a next-generation Boltbody ISAC that targets the tumor-associated antigen claudin 18.2 for the treatment of gastric/gastroesophageal junction cancer, pancreatic cancer, and other tumor types; BDC-3042, a dectin-2 agonist antibody program for the treatment of non-small cell lung cancer, melanoma, and other solid tumors; CEA ISAC, a Boltbody ISAC targeting carcinoembryonic antigen cell adhesion molecule 5 for the treatment of solid tumors, including colorectal, non-small cell lung, pancreatic, and breast; and PD-L1 ISAC, a novel human anti-PD-L1 antibody conjugated to a next-generation TLR7/8 agonist payload via a non-cleavable linker to target both tumor and immune cells for the treatment of tumor regression and immunological memory. The company has collaboration agreements with Toray Industries, Genmab A/S, and Innovent Biologics, Inc.; and a license agreement with Stanford University. The company was formerly known as Bolt Therapeutics, Inc. and changed its name to Bolt Biotherapeutics, Inc. in July 2015. Bolt Biotherapeutics, Inc. was incorporated in 2015 and is headquartered in Redwood City, California.